Breaking News

Expedition Therapeutics Raises $165 Million in Oversubscribed Series A

Proceeds will advance EXPD-101 through a global Phase 2 study in chronic obstructive pulmonary disease (COPD).

Author Image

By: Charlie Sternberg

Associate Editor

Expedition Therapeutics has closed a $165 million Series A financing round to support development of its lead candidate, EXPD-101, a next-generation DPP1 inhibitor targeting neutrophilic inflammation in chronic obstructive pulmonary disease (COPD). The round was co-led by Sofinnova Investments and Novo Holdings, with participation from Forbion, Dawn Biopharma (KKR), Adage, Balyasny, Logos Capital, Sanofi Ventures, and existing backers BVF Partners and Venrock Healthcare Capital Partners. Proc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters